Effects of carbon monoxide exposure on serotonergic neuronal systems in rat brain

Life Sciences

Volumn 62, Issue 23, 1998, Pages 2101-2108

  Muraoka, M ^a   Hayakawa, H ^a   Kagaya, A ^a   Kojima, T ^a   Yamawaki, S ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

5 HT(2A) receptor; Brain; Carbon monoxide; Serotonin; Serotonin synthesis

Indexed keywords

3 HYDROXYBENZYLHYDRAZINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTOPHAN; KETANSERIN; SEROTONIN; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BINDING SITE; BRAIN REGION; CARBON MONOXIDE INTOXICATION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; FRONTAL CORTEX; HIPPOCAMPUS; HYPOTHALAMUS; MALE; MESENCEPHALON; NONHUMAN; RAT; SEROTONIN BRAIN LEVEL; SEROTONINERGIC SYSTEM;

ANIMALIA;

EID: 0032078339     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(98)00185-4     Document Type: Article

References (27)

1. 1. S.K. MIN, Acta Psychiatr. Scand. 73 80-86 (1986).
2. 2. D.G. PENNEY, Toxicology 62 123-160 (1990).
3. 3. A.J. BAKER, M.H. ZORNOW, M.S. SCHELLER, T.L. YAKSH, S.R. SKILLING, D.H. SMULLIN, A.A. LARSON and R. KUCZENSKI, J. Neurochem. 57 1370-1379 (1991).
4. 4. S. IIJIMA, K. HARA, H. SUGA, S. NAKAMURA and M. KAMEYAMA, Stroke 17 529-533 (1986).
5. 5. G.B. FREEMAN, P. NIELSEN and G.E. GIBSON, J. Neurochem. 46 733-738 (1986).
6. 6. D.A. RICHARDS, T.P. OBRENOVITCH, L. SYMON and G. CURZON, J. Neurochem. 60 128-136 (1993).
7. 7. T. KIRINO, Brain Res. 239 57-69 (1982).
8. 8. M.Y.T. GLOBUS, P. WESTER, R. BUSTO and W.D. DIETRICH, Stroke 23 1595-1601 (1992).
9. 9. T. NABESHIMA, A. KATOH, H. ISHIMARU, Y. YONEDA, K. OGITA, K. MURASE, H. OHTSUKA, K. INARI, T. FUKUTA and T. KAMEYAMA, J. Pharmacol. Exp. Ther. 256 378-384 (1991).
10. 10. H. ISHIMARU, T. NABESHIMA, A. KATOH, H. SUZUKI, T. FUKUTA and T. KAMEYAMA, Biochem. Biophys. Res. Commun. 179 836-840 (1991).
11. 11. J.N. DAVIS and A. CALSSON, J. Neurochem. 21 783-790 (1973).
12. 12. V. MACMILLAN, Brain Res. 408 40-46 (1987).
13. 13. M.B. NEWBY, R.J. ROBERTS and R.K. BHATNAGAR, J. Pharmacol. Exp. Ther. 206 61-68 (1978).
14. 14. H. FUJIKURA, H. KATO, T. ARAKI, H. BAN, Y. HASEGAWA and K. KOGURE, Brain Res. 636 103-106 (1994).
15. 15. J. KLISCH and K.M. BODE-GREUEL, Brain Res. 578 1-7 (1992).
16. 16. J.H.M. PREHN, M. WELSCH, C. BACKHAUSS, J. NUGLISCH, F. AUSMEIER, C. KARKOUTLY and J. KRIEGLSTEIN, Brain Res. 630 10-20 (1993).
17. 17. T. KOJIMA, Y. NISHIYAMA, M. YASHIKI and I. UNE, Jpn. J. Legal Med. 35 305-311 (1981).
18. 18. M. FUKUI, In: Saiban Kagaku, 2nd Ed. M. Fukui et al. (Eds), 239-246, Hirokawa. Tokyo (1972).
19. 19. A. CARLSSON, J.N. DAVIS, W. KEHR, M. LINDQVIST and C.V. ATACK, Naunyn-Schmiedeberg's Arch. Pharmacol. 275 153-168 (1972).
20. 20. J.E. LEYSEN, C.J.E. NIEMEGEERS, J.M. VAN NUETEN and P.M. LADURON, Mol. Pharmacol. 21 301-314 (1982).
21. 21. O.H. LOWRY, N.J. ROSEBROUGH, A.L. FARR and R.J. RANDALL, J. Biol. Chem. 193 265-275 (1951).
22. 22. M. HIRAMATSU, S. YOKOYAMA, T. NABESHIMA and T. KAMEYAMA, Pharmacol. Biochem. Behav. 48 9-15 (1994).
23. 23. J.H. TROUVIN, M. PRIOUX-GUYONNEAU, Y. COHEN and C. JACQUOT, Gen. Pharmacol. 17 69-73 (1986).
24. 24. P.A. BRODERICK and G.E. GIBSON, Metabolic Brain Disease 4 143-153 (1989).
25. 25. L.A. PHEBUS and J.A. CLEMENS, Life Sci. 44 1335-1342 (1989).
26. 26. B.B. MRSULJA, B.J. MRSULJA, M. SPATZ and I. KLATZO, Neurology 26 785-787 (1976).
27. 27. C.M. BROWN, A.T. KILPATRICK, A. MARTIN and M. SPEDDING, Neuropharmacology 27 831-836 (1988).